ATS Stat

HomeATS Stat ▶ Stat June 23, 2021
Stat June 23, 2021

Philips PAP Device Recall Resources

Recently, Philips issued a recall notice some of their positive airway pressure (PAP) devices due to potential health risks from the polyester-based polyurethane foam used in their devices. Specifically, the foam may degrade into particles that may be inhaled by the user.  The potential risks of degraded foam exposure are listed on the manufacturer's website.

View ATS resources here, and watch a webinar with experts from the American Academy of Sleep Medicine  (AASM), American Academy of Neurology, American College of Chest Physicians, Canadian Sleep Society, and the ATS. You can also view AASM guidance and Philips Guidance for Patients.


Tomorrow!  ATS and The Union TB Elimination Webinar, “Why Not Now?”

Prior to the declaration of the COVID-19 pandemic, the TB response was falling behind on the necessary timeline to meet the elimination goals outlined and reinforced by commitments made at the UN High Level meeting on TB in September 2018. In the last year, the impact of the COVID-19 on the TB response has set back the fight against TB by over a decade, to 2008 levels.

Join us for the second session in  The Union and ATS webinar series, discussing if the ambitious goals are still possible.

When: 9 a.m. ET, June 24, 2021
Register now!


Assembly Leadership Elections: Call for Nominations!

Nominate a colleague or yourself for an ATS assembly leadership position today! To see the list of open positions for the upcoming election cycle please visit the submission portal. Learn more!

Deadline: Aug. 30, 2021


CME Opportunity:  Emerging Treatment Strategies for the Management of Patients with Chronic Cough

In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough and summarize the current guidelines and emerging treatment strategies.

Full CME information is available on the site.

When: 2 p.m. ET, June 26, 2021
Register now!

Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


Upcoming Industry Innovations

 “Data Driven Approaches to Identify Progression and Optimize Outcomes in Interstitial Lung Disease”

In this webinar we will focus on research and care programs which use patient data to optimize management of ILD and discuss the key learnings from these fields.

When: 2 p.m. ET, June 23, 2021
Register now!

Sponsored by patientMpower

“Unclassifiable Interstitial Lung Disease: Update on Challenges and Successes”

In this webinar, the faculty will review the signs, symptoms, laboratory, histopathologic, and image findings that lead to better diagnosis of uILD, review their treatment strategies for managing patients with uILD, as well as discuss the clinical implications of new clinical trial findings on the safety and efficacy of emerging treatments in uILD.

When: 6:30 p.m. ET, July 6, 2021
Register now!

Sponsored by Genentech, a member of the Roche Group 

“REPLACE: (Riociguat rEplacing PDE5i therapy evaluated Against Continued PDE5i therapy):  A Look at Phase IV Study Data”

This virtual learning session will review the clinical data from a recent Phase IV study. 

Where: 12 p.m. ET, July 12, 2021
Register now!

Sponsored by Bayer

<!doctype html>